Derma Sciences Inc  

(Public, NASDAQ:DSCI)   Watch this stock  
Find more results for DSCI
3.05
-0.07 (-2.24%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.03 - 3.22
52 week 2.85 - 9.23
Open 3.14
Vol / Avg. 109,795.00/143,527.00
Mkt cap 78.71M
P/E     -
Div/yield     -
EPS -1.50
Shares 25.81M
Beta 1.13
Inst. own 91%
Jan 7, 2016
Full Year 2015 Derma Sciences Inc Earnings Release
Dec 2, 2015
Derma Sciences Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2015
Derma Sciences Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -40.43% -47.49%
Operating margin -42.02% -47.89%
EBITD margin - -43.18%
Return on average assets -29.79% -34.91%
Return on average equity -33.48% -39.24%
Employees 299 -
CDP Score - -

Address

214 Carnegie Ctr Ste 300
PRINCETON, NJ 08540-6237
United States - Map
+1-609-5144744 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Derma Sciences, Inc. (Derma Sciences) is a tissue regeneration company, which is engaged in the research and management of acute and chronic wounds, and burns. The Company operates through three segments: pharmaceutical wound care, advanced wound care and traditional wound care products. Pharmaceutical wound care products consist of DSC127, a product for the treatment of a variety of dermal applications, including diabetic foot ulcers and scar prevention. DSC127 for diabetic foot ulcers is in Phase III of clinical development and in pre-clinical stage of scar prevention. Advanced wound care products consist of differentiated dressings, bandages and ointments for wound healing and/or prevent infection, including MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closer strips, catheter fasteners and skin care products.

Officers and directors

Stephen T. Wills CPA Interim Executive Chairman of the Board, Principal Executive Officer
Age: 58
Bio & Compensation  - Reuters
John E. Yetter CPA Chief Financial Officer, Executive Vice President - Finance
Age: 62
Bio & Compensation  - Reuters
Robert C. Cole Group President - Traditional Wound Care and Corporate Accounts
Age: 62
Bio & Compensation  - Reuters
Barry J. Wolfenson Group President- Advanced Wound Care
Age: 48
Bio & Compensation  - Reuters
Frederic Eigner Executive Vice President - Operations; General Manager of Derma Sciences Canada, Inc.
Age: 65
Bio & Compensation  - Reuters
Bruce F. Wesson Vice Independent Lead Director
Age: 72
Bio & Compensation  - Reuters
Brett Donald Hewlett Director
Age: 52
Bio & Compensation  - Reuters
Edward J. Quilty Director
Age: 64
Bio & Compensation  - Reuters
Srini Conjeevaram Independent Director
Age: 56
Bio & Compensation  - Reuters
Robert G. Moussa Independent Director
Age: 67
Bio & Compensation  - Reuters